Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer Interventions: Biological: N-803; Drug: Aldoxorubicin HCl; Biological: PD-L1 t-haNK; Drug: Nab-paclitaxel; Drug: Gemcitabine; Drug: Cyclophosphamide; Drug: 5-Fluorouracil; Drug: Leucovorin; Procedure: SBRT; Drug: Irinotecan liposome Sponsor: ImmunityBio, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Pancreas | Pancreatic Cancer | Research